# US 2022/0285032 A1 · Determining Prognosis and Treatment based on Clinical-Pathologic Factors and Continuous Multigene-Expression Profile Scores

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0285032 A1
- Document ID: US20220285032A1
- Status: Published application
- Kind: A1
- Application number: 17/688,215
- Filed: 2022-03-07
- Published: 2022-09-08
- Earliest claimed: 2021-03-08
- Assignees: Castle Biosciences, Inc.
- Applicants: Castle Biosciences, Inc.
- Inventors: Kyle R. COVINGTON; Bernhard SPIESS; Ann QUICK; Sarah KURLEY
- Web page: https://patentgrep.com/patent/US20220285032A1

## CPC

- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 40/20: Supervised data analysis
- G16B 40/30: Unsupervised data analysis
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Example embodiments relate to determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores. An example embodiment includes a non-transitory, computer-readable medium having instructions stored thereon. The instructions, when executed by a processor, cause the processor to execute a method. The method includes obtaining a plurality of clinical-pathologic factors related to a patient. The clinical-pathologic factors are indicative of risk associated with melanoma. The method also includes obtaining a continuous multigene-expression profile score for the patient. The continuous multigene-expression profile score is based on multiple genes whose expressions are related to melanoma. Further, the method includes determining, based on the plurality of clinical-pathologic factors and the continuous multigene-expression profile score, a risk score for the patient. In addition, the method includes outputting the risk score for use in determining a prognosis and treatment plan.

## Claims

### Claim 1

A non-transitory, computer-readable medium having instructions stored thereon, wherein the instructions, when executed by a processor, cause the processor to execute a method comprising:
obtaining a plurality of clinical-pathologic factors related to a patient, wherein the clinical-pathologic factors are indicative of risk associated with melanoma;
obtaining a continuous multigene-expression profile score for the patient, wherein the continuous multigene-expression profile score is based on multiple genes whose expressions are related to melanoma;
determining, based on the plurality of clinical-pathologic factors and the continuous multigene-expression profile score, a risk score for the patient; and
outputting the risk score for use in determining a prognosis and treatment plan.

### Claim 2 (depends on 1)

The non-transitory, computer-readable medium of claim 1, wherein obtaining the continuous multigene-expression profile score comprises:
receiving a continuous multigene-expression profile for the patient based on multiple genes whose expressions are related to melanoma; and
calculating the continuous multigene-expression profile score based on the continuous multigene-expression profile.

### Claim 3 (depends on 1)

The non-transitory, computer-readable medium of claim 1, wherein the continuous multigene-expression profile score comprises a score between 0 and 1 that represents expressions of 31 different genes relating to melanoma.

### Claim 4 (depends on 1)

The non-transitory, computer-readable medium of claim 1, wherein the method further comprises:
obtaining, after outputting the risk score, one or more additional clinical-pathologic factors related to the patient;
calculating, based on the plurality of clinical-pathologic factors, the one or more additional clinical-pathologic factors, and the continuous multigene-expression profile score, a revised risk score for the patient; and
outputting the revised risk score for use in determining a prognosis and treatment plan.

### Claim 5 (depends on 1)

The non-transitory, computer-readable medium of claim 1, wherein outputting the risk score comprises:
generating a clinical laboratory report usable for patient care; and
causing an associated printing device to print the clinical laboratory report.

### Claim 6 (depends on 1)

The non-transitory, computer-readable medium of claim 1, wherein the plurality of clinical-pathologic factors comprises an age of the patient, a gender of the patient, a tumor site location, a histologic type, a Breslow thickness measurement, a transected base measurement, an ulceration measurement, a microsatellites measurement, a mitotic rate, a lymphovascular invasion measurement, a tumor infiltrating lymphocytes measurement, a tumor regression, a sentinel lymph node status, or an in-transit disease/satellites measurement.

### Claim 7 (depends on 1)

The non-transitory, computer-readable medium of claim 1, wherein the risk score comprises a sentinel lymph node (SLN) metastasis positivity, a recurrence-free survival (RFS) rate, a distance metastasis-free survival (DMFS) rate, or a melanoma specific survival (MSS) rate.

### Claim 8 (depends on 1)

The non-transitory, computer-readable medium of claim 1, wherein the method further comprises:
receiving user login credentials; and
validating the user login credentials by comparing the user login credentials to stored credentials associated with a plurality of authenticated users.

### Claim 9 (depends on 8)

The non-transitory, computer-readable medium of claim 8, wherein the plurality of authenticated users comprises physicians or clinicians permitted to provide and access information associated with the patient.

### Claim 10 (depends on 8)

The non-transitory, computer-readable medium of claim 8, wherein the plurality of authenticated users comprises the patient.

### Claim 11 (depends on 1)

The non-transitory, computer-readable medium of claim 1, wherein outputting the risk score comprises providing the risk score to an electronic health record associated with the patient.

### Claim 12 (depends on 1)

The non-transitory, computer-readable medium of claim 1,
wherein the plurality of clinical-pathologic factors are received from user input into a browser-based application,
wherein the continuous multigene-expression profile score for the patient is received from user input into the browser-based application, and
wherein outputting the risk score comprises displaying the risk score via the browser-based application.

### Claim 13 (depends on 1)

The non-transitory, computer-readable medium of claim 1,
wherein the plurality of clinical-pathologic factors are received from user input into a mobile application,
wherein the continuous multigene-expression profile score for the patient is received from user input into the mobile application, and
wherein outputting the risk score comprises causing an associated user interface to display the risk score via the mobile application.

### Claim 14 (depends on 1)

The non-transitory, computer-readable medium of claim 1, wherein the method further comprises:
determining, based on the plurality of clinical-pathologic factors, a range of risk scores for use in determining a prognosis and treatment plan; and
outputting the range of risk scores.

### Claim 15 (depends on 1)

The non-transitory, computer-readable medium of claim 1, wherein determining the risk score for the patient comprises applying a machine-learned model to the plurality of clinical-pathologic factors and the continuous multigene-expression profile score.

### Claim 16 (depends on 15)

The non-transitory, computer-readable medium of claim 15, wherein the machine-learned model comprises an artificial neural network, and wherein applying the machine-learned model to the plurality of clinical-pathologic factors comprises applying machine-learned weights of the artificial neural network to each of the clinical-pathologic factors and the continuous multigene-expression profile score.

### Claim 17 (depends on 1)

The non-transitory, computer-readable medium of claim 1, wherein determining the risk score for the patient comprises applying a statistical model to the plurality of clinical-pathologic factors and the continuous multigene-expression profile score.

### Claim 18

A method comprising:
determining a plurality of clinical-pathologic factors related to a patient, wherein the clinical-pathologic factors are indicative of risk associated with melanoma;
determining a continuous multigene-expression profile score for the patient, wherein the continuous multigene-expression profile score is based on multiple genes whose expressions are related to melanoma;
providing the plurality of clinical-pathologic factors and the continuous multigene-expression profile score to a computing device, wherein the computing device is configured to:
calculate, based on the plurality of clinical-pathologic factors and the continuous multigene-expression profile score, a risk score for the patient; and
output the risk score; and
modifying a prognosis or treatment plan based on the risk score.

### Claim 19 (depends on 18)

The method of claim 18, wherein modifying the prognosis or treatment plan based on the risk score comprises determining that further diagnostic testing is to be performed or performing further diagnostic testing.

### Claim 20 (depends on 18)

The method of claim 18, wherein modifying the prognosis or treatment plan based on the risk score comprises performing a sentinel lymph node (SLN) biopsy on the patient, wherein the method further comprises providing results from the SLN biopsy on the patient to the computing device, and wherein the computing device is further configured to:
calculate, based on the plurality of clinical-pathologic factors, the results from the SLN biopsy, and the continuous multigene-expression profile score, a revised risk score for the patient; and
output the revised risk score.

### Claim 21 (depends on 18)

The method of claim 18, wherein determining the continuous multigene-expression profile score comprises providing a continuous multigene-expression profile to the computing device, and wherein the computing device is further configured to calculate the continuous multigene-expression profile score based on the continuous multigene-expression profile.

### Claim 22 (depends on 18)

The method of claim 18, wherein determining the plurality of clinical-pathologic factors or determining the continuous multigene-expression profile score comprises:
performing one or more laboratory tests using one or more samples from the patient;
receiving demographic information from the patient; or
accessing one or more records associated with the patient.
